Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
Frontiers in Bioengineering and Biotechnology
|
March 3, 2020
miR-221-3p Delivered by BMMSC-Derived Microvesicles Promotes the Development of Acute Myelocytic Leukemia
Xuewu Zhang, Yu Xu, Jinghan Wang, et al.
Leukemia Research
|
August 21, 2013
Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy
Yinjun Lou, Shanshan Suo, Hongyan Tong, et al.
Blood
|
July 5, 2024
Homoharringtonine inhibits the NOTCH/MYC pathway and exhibits antitumor effects in T-cell acute lymphoblastic leukemia
Shanshan Suo, Dandan Zhao, Fenglin Li, et al.
European Journal of Immunology
|
October 16, 2012
Klf10 inhibits IL-12p40 production in macrophage colony-stimulating factor-induced mouse bone marrow-derived macrophages
Wei Zhang, Xuelian Wang, Xiaoping Xia, et al.
Leukemia Research
|
July 18, 2015
Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy
Yinjun Lou, Yafang Ma, Shanshan Suo, et al.
Hematological Oncology
|
June 5, 2018
Improved long-term survival in all Sanz risk patients of newly diagnosed acute promyelocytic leukemia treated with a combination of retinoic acid and arsenic trioxide-based front-line therapy
Yinjun Lou, Ying Lu, Zhijuan Zhu, et al.
American Journal of Hematology
|
July 19, 2023
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A single-arm, open-label, phase 2, multicenter study
Yi Zhang, Qike Zhang, Qingchi Liu, et al.
Pharmacology Research & Perspectives
|
May 2, 2025
Population Pharmacokinetics-Pharmacodynamics and Exposure-Response of Ropeginterferon Alfa-2b in Chinese and Japanese Patients With Polycythemia Vera
Albert Qin, Kazuya Shimoda, Shanshan Suo, et al.
Leukemia
|
September 26, 2021
Spred1 deficit promotes treatment resistance and transformation of chronic phase CML
Junjing Qiao, Chen Liang, Dandan Zhao, et al.
American Journal of Hematology
|
July 20, 2023
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study
Yi Zhang, Hu Zhou, Minghui Duan, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
Frontiers in Bioengineering and Biotechnology
|
March 3, 2020
miR-221-3p Delivered by BMMSC-Derived Microvesicles Promotes the Development of Acute Myelocytic Leukemia
Xuewu Zhang, Yu Xu, Jinghan Wang, et al.
Leukemia Research
|
August 21, 2013
Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy
Yinjun Lou, Shanshan Suo, Hongyan Tong, et al.
Blood
|
July 5, 2024
Homoharringtonine inhibits the NOTCH/MYC pathway and exhibits antitumor effects in T-cell acute lymphoblastic leukemia
Shanshan Suo, Dandan Zhao, Fenglin Li, et al.
European Journal of Immunology
|
October 16, 2012
Klf10 inhibits IL-12p40 production in macrophage colony-stimulating factor-induced mouse bone marrow-derived macrophages
Wei Zhang, Xuelian Wang, Xiaoping Xia, et al.
Leukemia Research
|
July 18, 2015
Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy
Yinjun Lou, Yafang Ma, Shanshan Suo, et al.
Hematological Oncology
|
June 5, 2018
Improved long-term survival in all Sanz risk patients of newly diagnosed acute promyelocytic leukemia treated with a combination of retinoic acid and arsenic trioxide-based front-line therapy
Yinjun Lou, Ying Lu, Zhijuan Zhu, et al.
American Journal of Hematology
|
July 19, 2023
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A single-arm, open-label, phase 2, multicenter study
Yi Zhang, Qike Zhang, Qingchi Liu, et al.
Pharmacology Research & Perspectives
|
May 2, 2025
Population Pharmacokinetics-Pharmacodynamics and Exposure-Response of Ropeginterferon Alfa-2b in Chinese and Japanese Patients With Polycythemia Vera
Albert Qin, Kazuya Shimoda, Shanshan Suo, et al.
Leukemia
|
September 26, 2021
Spred1 deficit promotes treatment resistance and transformation of chronic phase CML
Junjing Qiao, Chen Liang, Dandan Zhao, et al.
American Journal of Hematology
|
July 20, 2023
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study
Yi Zhang, Hu Zhou, Minghui Duan, et al.
Page
of 3